Key facts
- It has raised $11.3M; the latest was Grant ($1.2M) in Aug 2025.
- Notable investors include VIB, Bioqube Ventures, Flanders Future Techfund, Qbic Fund, VLAIO.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Spica Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Spica Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Spica Therapeutics
Operator of a proprietary platform intended to target disease-relevant macrophage subsets for therapeutic purposes. The company's platform uses functional macrophage fingerprinting technology to identify and selectively modulate pathogenic macrophages, with a focus on oncology, fibroinflammatory, and autoimmune diseases, enabling patients to improve and address unmet medical needs with the development of therapies.
- Sector
- Healthcare
- HQ
- Antwerp, Belgium
- Founded
- 2024
- Employees
- 6
- Website
- spicatx.com/
- Ownership
- Privately Held (backing)
Spica Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Spica Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Spica Therapeutics in its N-PORT filings yet. We sweep new filings monthly.